Guggenheim’s 2nd Annual Healthcare Innovation Conference :: Cabaletta Bio, Inc. (CABA)

Contact

Our RESET^TM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.

Guggenheim’s 2nd Annual Healthcare Innovation Conference

Webcast